Comprehensive review highlights anti-inflammatory properties and biological activities of Cercis chinensis, suggesting potential therapeutic use.
As a traditional plant with both ornamental and medicinal value, the pharmacological activity of Cercis chinensis is increasingly receiving attention from the academic community. Although modern research has confirmed its rich bioactive components, there is currently a lack of systematic chemical and pharmacological reviews. The objective of this review paper is to investigate the phytochemistry, biological activities, and extraction and separation techniques of C. chinensis, as well as its anti-inflammatory and analgesic effects. Literature review revealed 78 characteristic chemical components, including 32 flavonoids (1-32), 11 phenylpropanoids (33-43), four lignans (44-47), nine stilbenes (48-55), 10 polyketide derivatives (56-65), and 13 other components (66-78). By integrating and analyzing existing research data, the pharmacological activities of its extracts and monomer components in antioxidant, hypoglycemic, antibacterial, anti-Alzheimer's disease, and immune regulation were comprehensively evaluated. Based on network pharmacology strategies, a multidimensional network model of "components-targets-pathways" for C. chinensis was constructed for the first time, and 13 core active compounds and 46 key targets of anti-inflammatory and analgesic effects were screened. Molecular mechanism analysis shows that its anti-inflammatory and analgesic mechanisms mainly involve the regulation of interleukin-17 and tumor necrosis factor signaling pathways, with PTGS2 confirmed as the core target.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: